Pomerantz LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. over potential securities fraud. Investors who purchased or acquired Regeneron securities during the class period have until September 14, 2026, to seek appointment as lead plaintiff. The complaint follows two stock drops: on April 29, 2026, shares fell $45.41, or 6.21%, to $686.36 after the company disclosed changes to a Phase III study, and on May 16, 2026, shares fell $68.57, or 9.82%, to $629.68 after Regeneron announced the trial did not meet its primary endpoint of progression-free survival.
Regeneron Pharmaceuticals IncClass action lawsuit for securities fraud and trial failure disclosed.